A recent meta-analysis reported that higher serum ALA levels were significantly associated with a reduced CRC risk [54], and EPA has been shown to downregulate FADS1 expression, with evidence of chemopreventive effects in patients with familial adenomatous polyposis [55]. Here, FADS1 is linked to Familial adenomatous polyposis.